Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeHOSPITALSFeinstein Institutes for Medical Research Finds Extended Drug Treatment Reduces Blood Clots...

Feinstein Institutes for Medical Research Finds Extended Drug Treatment Reduces Blood Clots in Discharged Patients, a Side-effect of Recovering COVID-19 Patients

June 22, 2020

Feinstein Institutes for Medical Research reports post-hospitalized patients, especially recently discharged coronavirus disease 2019 (COVID-19) patients, are at higher risk for major thromboembolic events or the formation of blood clots that could lead to death.

New research published today in the Journal of the American College of Cardiology shows promise in the extended use of the drug rivaroxaban, a direct oral anticoagulant (DOAC), to prevent those adverse events.

A team of doctors and scientists from multiple international health care research institutes, led by Alex Spyropoulos, MD, professor at the Feinstein Institutes for Medical Research, (Northwell Health) analyzed the first set of data from a previous large clinical trial titled MARINER (NCT02111564). The team looked at the extended treatment of 10mg rivaroxaban for 45 days and if it reduced major arterial and venous thromboembolic events like venous thromboembolism (VTE), pulmonary embolism and stroke. Results showed that VTE, stroke, Myocardial infarction, and cardiovascular death were significantly reduced by 28 percent without an increase in major bleeding.

This study has particular relevance for hospitalized patients infected with the COVID-19 virus, as early research suggests those patients are prone to suffer arterial thromboembolism, including strokes and death, as well as venous thrombosis both in the hospital and after discharge.

“We are encouraged by the study’s results to potentially reduce these life-threatening thromboembolic episodes by expanding the use of rivaroxaban for patients post-hospitalization,” said Dr. Spyropoulos. “Through this research, Northwell Health has adapted its treatment policy for discharged COVID-19 patients, and others at risk, across the health system.”

In the trial, a total of 4,909 patients were assigned to the rivaroxaban treatment group and 4,913 patients in the placebo group. Additional results show that symptomatic lower extremity deep vein thrombosis (DVT) reduced 80 percent in those treated with rivaroxaban. In 2019, the Food and Drug Administration (FDA) approved a 10mg dose of rivaroxaban to treat hospitalized medically ill patients with extended thromboprophylaxis.

“Dr. Spyropoulos’ findings provide important guidance to significantly protect patients from potentially fatal clots,” said Kevin J. Tracey, MD, CEO and president of the Feinstein Institutes. “As a leader in this field, his new findings point the way to new standards of care at Northwell Health and likely other institutions worldwide.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy